<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01622361</url>
  </required_header>
  <id_info>
    <org_study_id>KBCSG012</org_study_id>
    <nct_id>NCT01622361</nct_id>
  </id_info>
  <brief_title>Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer</brief_title>
  <acronym>NEST</acronym>
  <official_title>A Phase III, Open-Label, Prospective, Randomized, Multicenter, Neo-adjuvant Study of Chemotherapy Versus Endocrine Therapy in Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korean Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare neo-adjuvant therapy of cytotoxic chemotherapy versus&#xD;
      GnRHa with tamoxifen , of response rate(RR) in patients of hormone responsive and HER2&#xD;
      negative, lymph node positive, primary breast cancer in premenopausal women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Primary objective&#xD;
&#xD;
           : Response Rate-MRI and/or Caliper&#xD;
&#xD;
        2. Secondary objectives&#xD;
&#xD;
             -  Pathologic complete response&#xD;
&#xD;
             -  Rate of conservation surgery&#xD;
&#xD;
             -  Ki-67 changes and its relationship to treatment response&#xD;
&#xD;
             -  Length of time to maximum response within the treatment period&#xD;
&#xD;
             -  Tolerability of two treatments&#xD;
&#xD;
             -  Disease-free survival(DFS)&#xD;
&#xD;
             -  Overall survival&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy Adriamycin+Cyclophosphamide&gt;Docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endocrine therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endocrine therapy(GnRHa with Tamoxifen) group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin+Cyclophosphamide&gt;Docetaxel</intervention_name>
    <description>Adriamycin 60mg/m2 + Cyclophosphamide 600mg/m2&#xD;
Route: by slow intravenous bolus&#xD;
Schedule: every 3weeks for 4 cycle&#xD;
Docetaxel 75mg/m2&#xD;
Route: intravenous as per local practice&#xD;
Schedule: every 3weeks for 4 cycle</description>
    <arm_group_label>Chemotherapy Group</arm_group_label>
    <other_name>Chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRHa with Tamoxifen</intervention_name>
    <description>Goserelin(GnRHa) 3.6mg&#xD;
Route: subcutaneously under the abdominal skin&#xD;
Schedule: every 4weeks for 6cycles (period of 34 days between 2 administrations must not be exceeded)&#xD;
Tamoxifen 20mg/day&#xD;
Route: Oral&#xD;
Schedule: everyday</description>
    <arm_group_label>Endocrine therapy group</arm_group_label>
    <other_name>Endocrine Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically proven primary invasive breast cancer which is thought to be suitable&#xD;
             for neo-adjuvant treatment&#xD;
&#xD;
          2. Pathologically proven lymph node positive tumor(FNAB or Core biopsy)&#xD;
&#xD;
          3. Tumor must be ER positive(eligible patients include Allred score 5 and more, Modified&#xD;
             Allred 4 and more) and HER-2 negative(IHC score is 0-1+; If IHC score is 2+, the&#xD;
             result of FISH or SISH is negative)&#xD;
&#xD;
          4. Premenopausal women&#xD;
&#xD;
             Premenopausal status as defined by :&#xD;
&#xD;
               -  Last menses within 6 month of randomization or&#xD;
&#xD;
               -  For patients who have had a unilateral oophorectomy, E2 ≥ 20PG/mL and FSH &lt;&#xD;
                  30mIU/Ml within 4 weeks of randomization&#xD;
&#xD;
          5. over 20 years old&#xD;
&#xD;
          6. Pre-treatment haematology and biochemistry values within acceptable limits :&#xD;
&#xD;
               -  ANC ≥ 1.5 × 109/l&#xD;
&#xD;
               -  Hb &gt; 9g/dl&#xD;
&#xD;
               -  Platelets ≥ 100 × 109/l&#xD;
&#xD;
               -  AST/ALT ≤ 1.5 × ULN(Upper Limit of Normal)&#xD;
&#xD;
               -  ALP ≤ 1.5 × ULN&#xD;
&#xD;
               -  Serum bilirubin ≤ 1.5 × ULN&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 × ULN&#xD;
&#xD;
          7. ECOG PS of 0 or 1&#xD;
&#xD;
          8. No concomitant medical, psychiatric or geographic problems that might prevent&#xD;
             completion of treatment or follow-up&#xD;
&#xD;
          9. Before any study-specific procedures, the appropriate written informed consent must be&#xD;
             obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inflammatory breast cancer&#xD;
&#xD;
          2. Inoperable disease that is judged very unlikely to be rendered operable by&#xD;
             neo-adjuvant treatment&#xD;
&#xD;
          3. Known severe hypersensitivity to GnRHa treatment&#xD;
&#xD;
          4. Bilateral invasive breast cancer&#xD;
&#xD;
          5. Other serious illness or medical condition:&#xD;
&#xD;
               -  congestive heart failure or unstable angina pectoris, previous history of&#xD;
                  myocardial infarction within 1 year from study entry, uncontrolled hypertension&#xD;
                  or high-risk uncontrolled arrhythmias&#xD;
&#xD;
               -  history of significant neurologic or psychiatric disorders including psychotic&#xD;
                  disorders, dementia or seizures that would prohibit the understanding and giving&#xD;
                  of informed consent&#xD;
&#xD;
               -  active uncontrolled infection&#xD;
&#xD;
          6. HRT within 4 weeks of starting treatment&#xD;
&#xD;
          7. Definite contra-indications for the use of corticosteroids.&#xD;
&#xD;
          8. Last 10 years with a history of other malignant tumor (except in the case of basal&#xD;
             cell carcinoma or cervical carcinoma in situ, and where treatment consisted solely of&#xD;
             resection)&#xD;
&#xD;
          9. Systemic metastatic (Tests for the diagnosis of systemic metastatic comply with the&#xD;
             guideline in each institution)&#xD;
&#xD;
         10. Pregnant or breastfeeding women&#xD;
&#xD;
         11. Chronic oral treatment with corticosteroids unless initiated &gt; 6 months prior to study&#xD;
             entry and at low dose (≤ 20 mg methylprednisolone or equivalent).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahn Sei Hyun, MD.PhD</last_name>
    <phone>82-2-3010-3490</phone>
    <email>ahnsh@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahn Sei Hyun, M.D.</last_name>
      <phone>82-2-3010-3490</phone>
      <email>ahnsh@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>A. S. Hyun, MD.PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>June 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2012</study_first_posted>
  <last_update_submitted>September 26, 2013</last_update_submitted>
  <last_update_submitted_qc>September 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sei-Hyun Ahn</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant</keyword>
  <keyword>endocrine therapy</keyword>
  <keyword>premenopausal</keyword>
  <keyword>hormone responsive</keyword>
  <keyword>HER2 negative</keyword>
  <keyword>lymph node positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

